STAT+: FDA approves Replimune melanoma drug previously rejected twice

MAP Verified Summary — reported by STAT News

The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at STAT News →

View MAP Context →